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Abstract
Background: Few countries in sub-Saharan Africa know the magnitude of their HIV epidemic among people who
inject drugs (PWID). This was the first study in Mozambique to measure prevalence of HIV, HBV, and HCV, and to
assess demographic characteristics and risk behaviors in this key population.
Methods: We used respondent-driven sampling (RDS) to conduct a cross-sectional behavioral surveillance survey of
PWID in two cities of Mozambique lasting six months. Participants were persons who had ever injected drugs
without a prescription. Participants completed a behavioral questionnaire and provided blood specimens for HIV,
hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV) testing. We performed RDS-adjusted
analysis in R 3.2 using RDSAT 7.1 weights.
Results: We enrolled 353 PWID in Maputo and 139 in Nampula/Nacala; approximately 95% of participants were
men. Disease prevalence in Maputo and Nampula/Nacala, respectively, was 50.1 and 19.9% for HIV, 32.1 and 36.4%
for HBsAg positivity, and 44.6 and 7.0% for anti-HCV positivity. Additionally, 8% (Maputo) and 28.6% (Nampula/
Nacala) of PWID reported having a genital sore or ulcer in the 12 months preceding the survey. Among PWID who
injected drugs in the last month, 50.3% (Maputo) and 49.6% (Nampula/Nacala) shared a needle at least once that
month. Condomless sex in the last 12 months was reported by 52.4% of PWID in Maputo and 29.1% in Nampula/
Nacala. Among PWID, 31.6% (Maputo) and 41.0% (Nampula/Nacala) had never tested for HIV. In multivariable
analysis, PWID who used heroin had 4.3 (Maputo; 95% confidence interval [CI]: 1.2, 18.2) and 2.3 (Nampula/Nacala;
95% CI: 1.2, 4.9) greater odds of having HIV.
Conclusion: Unsafe sexual behaviors and injection practices are frequent among PWID in Mozambique, and likely
contribute to the disproportionate burden of disease we found. Intensified efforts in prevention, care, and
treatment specific for PWID have the potential to limit disease transmission.
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Background
People who inject drugs (PWID) are at high risk of ac-
quiring and transmitting blood-borne viruses, including
HIV, from unsafe injection practices and risky sexual
behaviors. The United Nations Office on Drugs and
Crime (UNODC) estimates that around 29.5 million
people suffer from drug use disorders worldwide [1] of
the estimated 15.6 million PWID in the world, sub-
Saharan Africa has 1.4 million. The Southern and
Eastern coasts of Africa are important routes for global
heroin trafficking originating from Asia, and the region
is fast becoming a final destination for these drugs, with
a growing number of African consumers [2–4].
HIV prevalence among PWID is 18% globally [3],
nearly 28 times higher than HIV prevalence among the
general adult population [5]. A systematic review deter-
mined that HIV prevalence among PWID in sub-
Saharan Africa was 56% [3], but estimates in the region
vary widely [3].
Adverse health outcomes among PWID are further in-
tensified by punitive legal environments, a variety of
human rights abuses and poor access to services [6, 7].
Few harm reduction programs and PWID-specific HIV
prevention, care and treatment services are available in
sub-Saharan Africa [8–10]. As of 2017, only seven
countries had publicly funded syringe exchange and
medication-assisted opioid treatment programs [11]. In
Mozambique, publicly funded harm reduction and HIV
care and treatment programs for PWID did not exist
prior to this study.
An estimated 13.2% of the adult population in
Mozambique are living with HIV [12–16]; the percent-
age of PWID living with HIV was unknown. Information
on blood-borne disease burden and demographic and
behavioral characteristics of PWID are necessary to as-
sess the unique prevention, care and treatment needs of
this population. For this purpose, we conducted the first
biological and behavioral survey (BBS) among PWID in
two urban areas of Mozambique. PWID are one of five
priority populations surveyed as part of the national HIV
behavioral surveillance system, which include men that
have sex with men, female sex workers, long-distance
truck drivers, and mine workers [17–20]. This manu-




Prior to conducing the PWID BBS, we conducted forma-
tive assessments consisting of 7 focus groups and 22 key
informant interviews with 86 participants in Maputo and
Nampula/Nacala in July 2013 to identify the feasibility of
using respondent-driven sampling for reaching PWID in
the survey cities. In each city, community outreach
workers collaborated with a community liaison coordin-
ator, a survey supervisor and survey interviewers to
design a participant recruitment plan for formative as-
sessment. These assessments answered operational and
logistical questions related to survey implementation,
and obtained information from PWID and providers,
such as locations of injection use and availability of
health and social services. Formative assessment found
that RDS would be a feasible methodology, that PWID
were highly networked from diverse social background,
and that most PWID were men. In terms of risk behav-
iors, needle sharing was a common practice, and that
there was little access to harm reduction service. In
terms of study operation, formative assessment deter-
mined that incentives to help cover cost of transport and
time would be helpful, fingerprick was preferable to ven-
ous blood draw, participants would be willing to test for
HIV, HBV and HCV [21].
Study setting
From October 2013 to March 2014, we conducted a
cross-sectional biobehavioral survey using respondent-
driven sampling (RDS) methodology in Maputo and
Nampula/Nacala. Maputo, the capital city, is located in
the South and is the most populous city in the country,
while Nampula, located in the North, and the second
most population city. These was selected as survey cities
as a result of stakeholder consultations that assessed
programmatic data, civil society organizations that re-
ported a large number of PWID in the area. Both are
also important port cities for the trafficking of heroin
from Asia to South Africa and eventually Europe [4]. A
satellite site was established in Nacala city, 200 km from
Nampula because PWID in that city shared the same so-
cial network as those in Nampula. Survey sites were pri-
vate venues rented for the purpose of the survey. Access
to sites was restricted to survey teams and to persons
with a survey coupon. Survey sites were staffed by a
supervisor, a coupon manager, a receptionist, three in-
terviewers, three testing counselors, and a security
guard. Survey teams received two weeks of training on
PWID, human subjects research, and RDS. The training
comprises theoretical presentations as well as survey
simulations, facilitated by the survey investigators.
Participant eligibility
Persons were eligible to participate if they were 18 years
of age or older and lived, worked, or socialized in the
survey area during the six months preceding the survey,
were in possession of a valid referral coupon, and had
not previously participated in the current round of the
study. Additionally, persons who participated in the sur-
vey prior to October 2013 must have injected drugs
without a prescription in the 12months preceding the
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survey. Due to bottlenecks in social networks, starting in
December 2013, we received ethical review board ap-
proval to alter expand our inclusion criteria to include
any person who had ever injected drugs without a
prescription. During participant eligibility screening,
community outreach workers, current or prior injection
drug users themselves, further assisted interviewers in
determining participant eligibility by assessing whether
or not participants were familiar with the local injection
drug use culture.
Participant recruitment and sample size
RDS combines non-probability snowball sampling with
mathematical modeling to weight a non-randomly se-
lected sample to generate probability-based population
estimates [22]. Participant recruitment began with ‘seeds’
(initial participants) who were purposively selected in
consultation with key informants within the PWID
community. All seeds were selected before the study
began, but only three seeds were given coupons at the
beginning of the study at each site. In Nampula, two
additional seeds were given coupons one month after
initiation, and two more the month after. In Maputo,
two seeds were given coupons two months after initi-
ation. In order to cover different subgroups of the target
population, seeds were selected based on diverse charac-
teristics including sex, age, education and neighborhood
of drug purchase or consumption. Additionally, seeds
had large social network sizes and were able to recruit
peers. Each seed received three to five recruitment
coupons to recruit peers after participating in the study.
Their peers who then participated in the survey were
also given three to five coupons to recruit their peers.
Coupons received a brief training given the coupon
manager on how to recruit their peers and an informa-
tion sheet explaining the process. Coupons were tracked
using RDSCM, v 3.0 and on a manual log book.
This process was repeated with subsequent recruits
until the sample size was met and/or equilibrium was
achieved. To ensure that participants did not participate
more than once, there was only one survey site per city
staffed by the same people during opening hours, com-
munity outreach workers who were current injectors
were trained to be aware of who had already partici-
pated, and the coupon manager would note specific
participant markings (e.g. tattoos and scars). The target
sample size was set at 350 in each city based on the abil-
ity to provide 5% absolute precision around an estimated
prevalence of 15% with a design effect of 2.3. The only
available estimate of HIV among PWID in Mozambique
came from survey of incarcerated persons which found
prevalence of 32.1% in 2006 [23]. We estimated preva-
lence among non-incarcerated populations of PWID to
be about half that of incarcerated persons’. Equilibrium
is the point at which the RDS sample proportions for
key variables no longer change (or change very minim-
ally) no matter how many more people are recruited;
equilibrium was monitored weekly throughout survey
implementation. In Nampula/Nacala the desired sample
size was not met, although efforts were made to improve
recruitment, such as by improving outreach and educa-
tion using community outreach workers who were
themselves PWID and by increasing the number of
coupons given to each participant to five. Although the
sample size was lower than anticipated, we assessed
equilibrium for key variables, including age, HIV status,
length of time of drug use, drug of choice, to ensure that
these proportions had stabilized over enrollment.
Participants received a prevention and hygiene kit,
which included toothpaste, toothbrush, razor, band aids,
alcohol swabs, soap, condoms, lubricants and health
information, for participating in the survey. They also re-
ceived 50 MZN (~US$2.50 at the time of survey) in cash
for compensation of transportation costs. Participants
received a mobile phone card worth 50 MZN for each
referred peer who completed the survey. Each partici-
pant could refer up to five peers.
Behavioral questionnaire
Behavioral data were collected via a structured interview
using Questionnaire Development System (QDS™) ver-
sion 2.6.1 (NOVA Research Company, Silver Spring,
MD). The survey tool included questions related to par-
ticipant socio-demographic characteristics, sexual and
injection risk practices potentially related to HIV, HBV,
HCV infections and other sexually-transmitted infec-
tions (STI), violence and discrimination, and utilization
of health services. Individual social network sizes, re-
quired for RDS analyses, were measured by asking
“Approximately how many people who inject drugs do
you personally know by name who also know your
name?” The survey tool was developed in Portuguese
and English and offered in both languages. Tools were
pre-tested with PWID.
Biological sample collection and testing
Participants were offered HIV counseling and testing
consistent with national HIV testing guidelines using a
serial algorithm that screens with Determine™ HIV-1/2
(Alere, USA), and confirms with Uni-Gold HIV™ (Trinity
Biotech, Ireland) [24]. Following national norms, partici-
pants reporting a prior HIV positive test result were not
retested during this study. HIV prevalence estimates
were based on a combination of HIV rapid test results
and self-reported seropositivity. All blood used for
point-of-care tests and for preparation of Whatman™
903 filter paper were collected by a single finger prick
from consenting participants. Dried blood spots were
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used for external quality control, and 2% of the negative
samples and 5% of the randomly positive samples were
sent to the regional reference laboratory for HIV testing
(National Institute for Communicable Diseases in South
Africa Republic); concordance was 97.7%.
Point-of-care testing for HBsAg (Alere Determine®
HbsAg, Abbott Laboratories, UK) and anti-HCV (SD
Bioline HCV, Standard Diagnostics, Korea), regardless of
prior testing history, was provided during the survey.
While a reactive HBsAg test indicates the person is cur-
rently infected with either acute or chronic hepatitis B, a
reactive anti-HCV test indicates either current viremia
or a past HCV infection that resolved naturally or was
cured with treatment. Central hepatitis B tests were per-
formed using ELISA Murex® HBsAg Version 3 (Murex
Biotech Limited, UK) at the National Institute of Health
Laboratory, following internal quality controls, and was
used to estimate prevalence in the survey; centralized
anti-HCV testing was not performed.
A unique participant sequential code was used to link
test results to survey data. All point-of-care test results
were returned to participants promptly after test com-
pletion. Centralized testing results were not returned as
these tests were for quality control purposes only. All
participants who tested positive on any point-of-care test
received counseling and referrals for follow-up care
within the national health system using referral coupons.
Participants who had their coupons stamped at the re-
ferral health clinic were reimbursed the value of public
transportation to the clinic (50 MZN or approximately
US$2.50). Hepatitis C treatment was not available in the
country at the time of the study.
Data analysis
Diagnostic procedures, including analysis of homophily
and convergence, were run to ensure that data met the
underlying assumptions of RDS. Population point preva-
lence estimates and bootstrapped 95% confidence
intervals, shown in Tables 1, 2, 3, and 4, were produced
using the RDS-1 enhanced data smoothing estimator in
RDSAT 7.1 (Cornell University, Ithaca, NY). In RDSAT,
the number of re-samples for bootstrap was set to 15,
000 and the algorithm type as “enhanced data-
smoothing” as recommended by software developers
[17]. Seeds were included in analysis. A participant was
considered to be sexually active if he or she reported
having had one or more sexual partners in the last 12
months. Participants reporting no sexual partners in the
last 12 months were not asked questions related to re-
cent sexual behaviors. The outcome measure of interest
presented in this analysis is HIV status. All individuals
with a positive on-site HIV test and those who reported
knowing their HIV positive status who did not test on
site were classified as having HIV. Individuals who tested
Table 1 RDS-adjusted point estimates and confidence intervals of socio-demographic characteristics of people who inject drugs in
Mozambique, 2013–2014
Maputo (n = 353) Nampula/Nacala (n = 139)
na Crude Adj b % 95% CI na Crude Adj b % 95% CI
Sex
Male (vs Female) 332 94.1 92.9 87.8–97.1 135 97.1 97.0 92.6–100
Age (Years), median [IQR]c 33 [19, 56] 28 [18, 60]
18–24 37 10.5 12.5 7.7–17.0 55 39.6 42.6 30.1–56.7
25–34 179 50.7 54.4 47.4–60.6 50 36.0 34.5 24.1–45.3
≥ 35 137 38.8 33.1 27.6–40.6 34 24.5 22.9 12.0–34.4
Marital status
Single (never married) 226 64.0 65.4 58.7–72.1 63 45.3 49.7 38.4–61.8
Married or in a conjugal union 55 15.6 16.7 10.9–23.1 48 34.5 32.1 21.7–43.5
Separated, widowed or divorced 72 20.4 17.8 13.1–23.0 28 20.1 18.3 9.6–27.6
Education
Primary and below 181 51. 4 57.0 49.5–64.0 29 20.9 28.4 16.5–40.6
Missing 1 – – – – –
Primary language spoken at home
Portuguese (vs Other) 270 76.5 71.4 64.4–78.3 105 75.5 67.6 55.1–79.7
Nationality
Mozambican (vs Other) 351 99.4 99.8 99.4–100 132 95.0 96.7 93.2–99.3
a Sample includes seeds; no missing responses unless specified
b Estimates and 95% confidence intervals (CI) adjusted for RDS survey design using RDS-I (DS) estimator produced with RDSAT 7.1
c IQR Interquartile range
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negative or had an indeterminate result were classified
as negative. Individuals who refused testing and did not
report having had a prior HIV positive test result were
classified as missing. Design effect for the outcome of
interest was 2.6 for Maputo and 1.5 for Nampula. Sensi-
tivity analysis was performed classifying individuals with
missing status as positive and negative.
Individual weights based on the outcome of interest
(HIV status) were generated in RDSAT and exported to R
to be used in bivariable and multivariable analysis
(presented in Table 5). Logistic regression, using the svyglm
command for complex weighted surveys, was used to
model associations with HIV status. Data-driven
categorization was used for continuous variables. Variables
considered for modeling (listed in Tables 1, 2, 3, and 4)
were selected a priori based on evidence in the literature
about associations with HIV and potential confounders.
Those that in bivariable analysis were significant at P < 0.2
in any of the two cities, those that are known confounders
(i.e., education and gender) and those presenting
Table 2 RDS-adjusted point estimates and confidence intervals of behavioral characteristics related to drug consumption among
people who inject drugs in Mozambique, 2013–2014
Maputo (n = 353) Nampula/Nacala (n = 139)
na Crude Adjb % 95% CI na Crude Adjb % 95% CI
Age (in years) of first injection drug use, median [IQR] 24 [9, 46] 20 [14, 47]
< 18 37 10.9 7.0 4.5–10.7 19 13.7 9.6 4.6–15.0
18–24 152 44.7 48.8 41.9–55.4 83 59.7 60.1 50.5–70.3
≥ 25 151 44.4 44.2 36.9–50.8 37 26.6 30.3 19.8–40.7
Missing 13 – – 0 – –
Years since injection initiation, median [IQR] 7 [0, 35] 5 [0, 29]
0 11 3.2 4.4 1.4–7.7 5 3.6 5.1 1.6–9.6
1–5 122 35.9 41.6 34.5–50.7 72 51.8 52.2 40.9–63.2
6–10 87 25.6 25.1 18.0–30.6 27 19.4 19.8 12.8–29.7
≥ 11 120 35.3 28.9 22.7–36.0 35 25.2 22.9 12.2–33.0
Missing 13 – – 0 – –
Drug most commonly injected
Heroin 305 86.6 82.2 76.0–87.7 105 76.1 73.3 62.0–84.0
Cocaine 47 13.4 17.8 12.3–24.0 18 13.0 14.0 5.4–22.3
Other (including crack and cocktail mixes) 0 0.0 0.0 15 10.9 12.7 6.1–22.5
Missing 1 – – 1 – –
Frequency of injection drug use, last 12 months
Did not inject, last 12 months 18 5.1 8.6 3.9–13.9 7 5.0 3.8 0.3–8.1
A few times per year 17 4.8 5.0 2.2–9.0 12 8.6 10.9 4.1–19.3
A few times per month 39 11.0 10.8 6.9–15.0 31 22.3 33.5 22.4–46.7
A few times per week 39 11.0 13.6 9.0–19.1 54 38.8 32.4 23.2–40.6
Daily 240 68.0 62.0 54.4–69.4 35 25.2 19.4 11.3–29.5
Ever shared a syringe or needle, lifetime
Yes (vs No) 189 53.5 50.3 43.0–57.6 69 49.6 42.4 31.0–55.0
Injected drugs, last month
Yes (vs No) 267 75.9 67.5 58.6–76.7 124 89.2 92.8 87.9–98.0
Missing 1 – – 0 – –
Number of people with whom shared needles or syringes, last month
0 248 70.3 74.1 67.6–79.6 98 70.5 70.8 61.8–80.2
1–2 26 7.4 6.8 3.9–10.5 24 17.3 18.3 9.7–26.5
≥ 3 55 15.6 14.1 9.6–19.3 17 12.2 11.0 5.5–17.4
Shared, but doesn’t remember with how many 24 6.8 5.1 2.4–8.4 0
a Sample includes seeds; no missing responses unless specified
b Adjusted estimates and 95% confidence intervals (CI) produced with RDSAT 7.1
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unexpected outcomes (i.e., prior incarceration) were then
selected for multivariable modeling. Missing values were
excluded from analysis; and variables related to most re-
cent sexual partner were not considered in analysis because
only participants with a sexual partner in the last 12
months were asked these questions. Interaction effects and
multicollinearity between variables were ascertained during
modeling. Several models were developed, and the Akaike
Information Criteria was used to systematically remove
variables.
Ethical considerations
Participants were asked to provide written informed
consent for each study component: questionnaire, HIV,
HBV and HCV testing, and dried-blood spot sample
collection. No personal identifying information was
collected from participants. All data were collected on
encrypted password protected computers and




Recruitment took place from October 2013 to March
2014 and lasted approximately 21 weeks in Maputo and
23 weeks in Nampula/Nacala. Five seeds (20% female
and 20% > 40 years old) were selected in Maputo and
seven in Nampula/Nacala (14% female and 14% > 40
years old). From the five identified seeds in Maputo, only
three contributed to recruitment. The longest recruit-
ment chain in Maputo was comprised of 13 waves and
252 participants (71.4% of the total sample). In
Nampula/Nacala, seven seeds were identified, of which
five participated, and one contributed most substantially
to participant recruitment. The maximum number of
waves in Nampula/Nacala was 11 with 123 participants
Table 3 RDS-adjusted point estimates and confidence intervals of sexual risk behaviors among people who inject drugs,
Mozambique 2013–2014
Maputo (n = 353) Nampula/Nacala (n = 139)
na Crude Adj b % 95% CI na Crude Adj b % 95% CI
Number of sexual partners, last 12 monthsc
0 93 27.2 24.4 18.8–30.7 5 3.6 3.0 0.4–6.3
1 86 25.1 27.9 21.6–35.5 18 12.9 16.2 6.7–27.6
≥ 2 163 47.7 47.7 39.1–55.4 116 83.5 80.8 69.3–91.1
Missingd 11 – – – – –
Ever had sex in exchange for drugs, lifetime
Yes (vs No) 47 13.7 11.4 7.3–15.9 20 14.4 10.3 4.8–16.2
Missingd 11 – – 0 – –
Gave money, goods or services in exchange for sex, last 12 months
Yes (vs No) 114 33.3 30.3 24.5–37.2 89 64.0 65.7 55.2–76.2
Missingd 11 – – 0 – –
Received money, goods or services in exchange for sex, last 12 months
Yes (vs No) 60 17.5 17.5 12.2–22.6 42 30.2 27.3 17.5–38.1
Missingd 11 – – 0 – –
Had unprotected intercourse at last sex, last 12 monthsd,e
Yes (vs No) 131 52.0 52.4 44.8–61.6 42 31.1 29.1 19.3–40.3
Missingd 1 – – 0 – –
Last sexual partner injects drugs, last 12 monthsd,e
Yes (vs No) 31 12.5 10.0 5.7–15.9 8 6.0 4.6 1.5–8.8
Missingd 5 – – 1 – –
Shared a needle or syringe with last sex partner, last 12 monthsd,e
Yes (vs No) 14 5.6 4.5 1.8–85.0 3 2.2 2.0 0.0–5.1
Missingd 5 1
a Sample includes seeds; no missing responses unless specified
b Adjusted estimates and 95% confidence intervals (CI) produced with RDSAT 7.1
c Includes male and female partners of men that inject drugs and male partners of women that inject drugs
d Missing responses include those that had sexual partners and could not remember or refused to answer to the question
e Sub-analysis of persons who had sex in past 12 months in Maputo (n = 253) and Nampula/Nacala (n = 135)
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(88.5% of the total sample). Figure 1 illustrates the peer-
referral recruitment chains of PWID in the two areas of
Mozambique. Diagnostic tests revealed that RDS as-
sumptions had been met. Median network size was 15 in
Maputo and 10 in Nampula/Nacala.
A total of 1915 and 1210 coupons were distributed in
Maputo and Nampula/Nacala (up to five per participant)
respectively. Of those, 383 (20%) in Maputo and 241
(20%) in Nampula/Nacala were redeemed by individuals
who were screened for eligibility. A total of 353 PWID
were enrolled in the survey in Maputo (92% of individ-
uals screened) and 139 in Nampula/Nacala (58% of indi-
viduals screened). In both locations, most persons were
not eligible because they had not injected drugs in the
last 12 months prior to the survey (prior to criteria
change). A comparison of sample composition before
and after criteria change revealed no significant
differences.
Demographic characteristics of PWID
Most PWID in Maputo and Nampula/Nacala were men
(92.9 and 97.0%, respectively) and of Mozambican na-
tionality (99.8 and 96.7%) (Table 1). Median age of
PWID in Maputo was 33 years and 28 years in Nampula/
Nacala. In Maputo and Nampula/Nacala, 65.4 and 49.7%
of PWID, respectively, were single (never married). In
Maputo and Nampula/Nacala, 57.0 and 28.4% of PWID,
respectively, had a primary education level or below.
Portuguese was reported as the primary spoken language
among majority of respondents in both survey cities.
Table 4 RDS-adjusted point estimates and confidence intervals of health outcomes and service utilization among people who inject
drugs in Mozambique, 2013–2014
Maputo (n = 353) Nampula/Nacala (n = 139)
na Crude Adj b % 95% CI na Crude Adj b % 95% CI
Has access to new, unused syringes or needles 315 89.2 89.6 85.4–93.6 110 79.7 78.9 69.6–87.2
Missing 0 – – 1 – –
Had contact with a peer educator, last 12 months 40 11.4 9.5 5.3–13.3 62 44.6 40.8 31.5–52.0
Missing 1 – – 0 – –
Received free condoms, last 12 months 100 28.6 26.8 21.0–33.7 88 63.3 60.0 49.2–71.3
Missing 3 – – 0 – –
Ever received treatment for overdose, drug
substitution therapy or detoxification, lifetime
16 4.5 2.5 1.2–4.1 37 26.6 23.7 16.4–31.9
Ever in a rehabilitation or a self-help group, lifetimec 12 3.4 2.5 0.9–4.8 26 18.7 14.3 7.8–22.1
Ever incarcerated, lifetime 264 74.8 72.2 66.4–78.0 64 46.0 42.6 29.9–52.9
Previous HIV test, lifetime 254 72.0 68.4 61.1–75.4 80 57.6 59.0 46.4–68.6
Previous HIV test, last 12 months 80 22.9 24.6 18.9–30.0 35 25.2 21.9 12.7–31.4
Missing 4 – – – 0 – –
Ever heard of Hepatitis B or C 138 39.1 34.7 28.3–41.4 73 52.5 52.1 40.8–617
Has HIV 179 56.1 50.1 40.1–59.0 25 19.8 19.9 10.9–29.2
Did not consent 34 13
Screen positive for Hepatitis B surface antigen 107 30.5 32.1 25.2–38.5 57 41.0 36.4 22.6–49.8
Did not consent 2 0
Hepatitis C antibodies 148 47.6 44.6 33.4–53.9 15 11.1 7.0 2.0–12.5
Did not consent 42 4
Has HIV & HBV surface antigen 49 15.4 14.9 9.1–19.5 10 7.9 8.3 2.4–14.9
Did not consent 35 13
Has HIV & HCV antibodies 116 38.7 36.1 26.4–45.8 8 6.5 4.1 0.6–8.4
Did not consent 53 15
Ever tested positive for HIV prior to the survey 123 34.9 29.0 22.1–44.3 10 7.2 5.8 1.7–11.2
Missing 1 1
Had a self-reported sore or ulcer in the genital
region, last 12 months
30 8.5 8.0 4.7–11.7 35 25.2 28.6 19.1–37.9
a Sample includes seeds; no missing responses unless specified
b Adjusted estimates and 95% confidence intervals (CI) produced with RDSAT 7.1
c Includes self-help groups, outpatient counseling, drug substitution therapy, detoxification program or rehabilitation
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Drug injection behaviors
Many PWID first injected drugs when they were 18–24
years old (48.8% in Maputo and 60.1% in Nampula/Na-
cala) (Table 2). Close to half (41.6% in Maputo and
52.2% in Nampula/Nacala) began injecting within 1–5
years prior to the survey. In Maputo, the majority of
PWID injected drugs daily (62.0%), whereas in Nam-
pula/Nacala 19.4% injected daily.
The most commonly injected drug was heroin in both
cities, 82.2% in Maputo and 73.3%, Nampula/Nacala.
Close to half (50.3% in Maputo and 42.4% in Nampula/
Nacala) of PWID had ever shared a needle or syringe,
and 14.1% in Maputo and 11.0% in Nampula/Nacala
shared a needle with ≥3 different persons in the last
month. In Maputo 14.3% and in Nampula/Nacala 8.0%
of PWID used a needle or syringe after someone else
had injected with it; and 24.9% (Maputo) and 22.7%
(Nampula/Nacala) passed on their used needle or syr-
inge to someone else (data not in table).
Sexual behaviors
Nearly half (47.7%) of PWID in Maputo, and the major-
ity (83.5%) in Nampula/Nacala, had ≥2 sexual partners
in the year preceding the survey (Table 3). One in ten or
Fig. 1 Recruitment networks in Maputo and Nampula/Nacala, BBS-PWID, 2013–2014. Seven seeds were selected in Maputo, of which five
participated in the survey and only three seeds recruited participants. The chain of one seed reached 252 participants, the second reached 80
participants, and the third chain reached19 participants. In Maputo the maximum number of recruitment waves was 13. Five seeds were selected
in Nampula/Nacala, however, only one seed recruited 123 of the participants in the survey. The maximum number of recruitment waves in
Nampula/Nacala was 11. In Maputo, all five seeds that participated in the survey were 35 years old or older and along the processes the
participants age become more diversified. In Nampula/Nacala the seed that contributed most in the recruitment of participants was in the 18–24
years old group, and subsequently there was an age diversification
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fewer (10.0% Maputo and 6.0% Maputo/Nacala) of
PWID had a sexual partner that also injected drugs. Half
(52.4%) of PWID in Maputo, and almost one third
(31.1%) in Nampula/Nacala had unprotected intercourse
the last time they had sex. In Maputo, 30.3% of PWID
gave money, goods, or services in exchange for sex in
the last 12 months, and 17.5% received money, good, or
services in exchange for sex. In Nampula/Nacala, 65.7
and 27.3%, did so respectively. Eight percent in Maputo
and 28.6% of PWID in Nampula/Nacala reported having
a genital sore or ulcer in the 12months preceding the
survey.
Access to programs
The majority of PWID in both Maputo and Nampula/
Nacala at 89.6 and 78.9%, respectively had access to new
or sterile syringes (Table 4). As far as contact with peer
educators, one in ten (9.5%) of PWID in Maputo and
40.8% in Nampula/Nacala had contact with a peer edu-
cator in the last 12 months. Just over one-quarter
(26.8%) and 60.0% of PWID in Maputo and Nampula/
Nacala had received free condoms in the 12months pre-
ceding the survey. In Maputo, 2.5% of PWID had ever
received treatment for overdose, drug substitution ther-
apy and detoxification, while in Nampula/Nacala this
proportion was 23.7%. Among PWID, 68.4% in Maputo
and 59.0% in Nampula/Nacala had been tested for HIV
at least once before this survey, and 24.6% in Maputo
and 21.9% in Nampula/Nacala had done so in the 12
months before the survey.
HIV, HBsAg, and anti-HCV positivity prevalence and
associated risks
The prevalence of HIV was 50.1% (95% CI: 40.1–59.0) in
Maputo and 19.9% (95% CI: 10.9–29.2) in Nampula/Na-
cala. Of the 179 participants classified as having HIV, 45
reported prior HIV-positive test result and were not
retested. In Nampula, of the 25 participants with HIV,
five did not test due to previous positive status. Sensitiv-
ity analysis which excluded individuals with self-reported
positive HIV status from analysis revealed that preva-
lence estimates were within the confidence bounds of
the prevalence estimate when individuals were retained
in the analysis. One third (33.5%) of HIV-positive PWID
in Maputo and two-thirds (66.0%) in Nampula/Nacala
were not aware of their HIV-positive status.
The prevalence of hepatitis B (acute or chronic)
among PWID was also high; 32.1% (95% CI: 25.2–38.5)
in Maputo and 36.4% (95% CI: 22.6–49.8) in Nampula/
Nacala. Anti-HCV positivity prevalence was 44.6% (95%
CI: 33.4–53.9) in Maputo and 7.0% (95% CI: 2.0–12.5) in
Nampula/Nacala. Co-infection of HIV and HBV was
found in 14.9% (95% CI: 9.1–19.5) of PWID in Maputo
and 8.3% (95% CI: 2.4–14.9) in Nampula/Nacala, while
the prevalence of HIV and anti-HCV positivity was
36.1% (95% CI: 26.4–45.8) in Maputo and 4.1% (95% CI:
0.6–8.4) in Nampula/Nacala.
Multivariable analysis of associations with HIV positiv-
ity among PWID in Maputo and Nampula/Nacala
(Table 5) found that the odds of having HIV was greater
among those injected drugs for the first time 6–10 years
prior to the study compared to 0–5 years prior (adjusted
odds ratio [aOR]: 2.0 [95% CI: 1.1–3.8] and 22.8 [95%
CI: 5.3–126.4], for Maputo and Nampula/Nacala, re-
spectively), and those that used heroin as their primary
drug of choice as compared to cocaine or other drugs
(aOR: 2.3 [95% CI: 1.2–4.9] and 4.3 [95% CI: 1.2–18.2],
for Maputo and Nampula/Nacala, respectively). In
Maputo, these odds were also greater among those who
ever shared a syringe or needle (aOR: 3.2 [95% CI: 1.9–
5.3]), injected daily (aOR: 2.0 [95% CI: 1.2–3.4]) and had
ever been tested for HIV (aOR: 2.3 [95% CI: 1.2–4.0]).
Those that had ever had sex in exchange for drugs had
lower odds of having HIV in Maputo (aOR: 0.5 [95% CI:
0.2–1.0]). In Nampula/Nacala HIV was associated with
prior incarceration (aOR: 3.2 [95% CI: 1.0–10.9]).
Additionally, no association was detected between HIV
status and level of education, marital status or language
in either city.
Discussion
This was the first study to measures burden of blood-
borne diseases and risk factors among PWID in
Mozambique. We found an alarmingly high prevalence
of HIV, HBsAg and anti-HCV among PWID. HIV preva-
lence among PWID (50.1% [95% CI: 40.1–59.0] in
Maputo and 19.9% [95% CI: 10.9–29.2] in Nampula) was
nearly four times higher than the prevalence of HIV
among adults in Mozambique (13.2% nationally, 16.9%
in Maputo, and 5.7% in Nampula Province) [16]. The
differences between the prevalence rates in Maputo
compared to Nampula are consistent with the regional
characteristics of the epidemic in the country, where
higher HIV prevalence is concentrated in the southern
region of the country given the historical economic and
cultural interaction with neighboring high-prevalence
countries, such as South Africa and Eswatini [16, 18].
Prevalence of HIV among PWID in our study is substan-
tially higher than in the prevalence of HIV among PWID
in other sub-Saharan African countries, including
Nigeria (3.1%), Seychelles (3.8%) and Madagascar (4.8)
[3]. While the PWID prevalence in Maputo is much
higher than estimates from PWID in South Africa (21%)
[19], Mauritius (45.5%), Kenya (42.0%), and also similar
(but less) than what is estimated in sub-Saharan region
(56% in 2017) [3].
This high burden of disease is especially concerning
because many of PWID with HIV were also coinfection
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with HBV and HCV which are known to contribute to
worse health outcomes [20]. The proportion of PWID
with HBV (as measured by HBsAg) in our study is simi-
lar that of PWID in other sub-Saharan countries [3], but
it is substantially higher than non-PWID untreated HIV-
infected living with HIV in Maputo which estimated the
prevalence to be 9.1% [25] and 12.2% among non-PWID
young people [14]. This high prevalence may be linked
to the fact that the hepatitis B vaccine is not yet available
to the general adult population in Mozambique through
the national immunization program.
Consistent with other studies among PWID in sur-
rounding countries [26–28], heroin was the most com-
monly injected drug among those who participated in
our study (81.3% in Maputo and 73.0% in Nampula/Na-
cala). Also consistent with the drug trafficking history in
the region, an expectedly high proportion of PWID (ap-
proximately one-quarter) initiated drug injection use
during the 10 years prior to the survey. Not surprisingly,
we found that PWID with a longer history of injection
drug use had greater odds of HIV infection [29, 30],
likely a result of longer exposure to injection-related risk
over time. In addition, 10 years prior to the survey
awareness of the modes of HIV transmission among
Mozambicans was low [31].
Despite the fact that the majority of participants re-
ported having access to new or sterile syringes, close to
half reporting having ever shared syringes, and about
one in ten used a needle or syringe after someone else
had used it the last time they injected drugs. This incon-
sistency of sterile needle availability versus sterile needle
use can potentially be explained by practices that are
perceived by PWID to reduce drug waste, including re-
use of their own needles, backload (a method of sharing
drugs between needles), flash blood (a method of sharing
blood of someone who injected) and sale of drugs in
pre-loaded syringes. These practices have been identified
in prior studies conducted in sub-Saharan Africa [32],
including in neighboring Tanzania [7]; however, further
investigation into the barriers to new, sterile syringe use
in the Mozambican context is needed. Interestingly, not
having access to new and unused syringes appeared to
be a protective factor of HIV among PWID. While this
may seem counterintuitive, we believe this is likely
because persons who knew they were at high-risk for
having HIV or already knew their HIV status were more
likely to have received prevention messages and would
know where to obtain sterile equipment. Nonetheless,
the finding of high access to new and unused syringes
but low utilization provides evidence for the importance
of targeted harm reduction interventions.
Although transmission of HIV among PWID is mostly
linked to injection drug use, sexual behaviors among
PWID should also be considered important in countries
generalized epidemics, such as Mozambique [33, 34].
Injection of stimulants, such as cocaine and metham-
phetamine, have been linked to high-risk sexual behavior
[35, 36]. Among sexually active PWID (72.8%) in our
study, approximately half in Maputo and nearly one in
three in Nampula reported not using a condom the last
time they had sex. Moreover, self-reported symptoms of
Sexual Transmitted Infections (STIs) were high among
PWID, reaching 28.6% in Nampula/Nacala. Sexual trans-
mission of HIV might play an especially important role
among PWID in Nampula, given that prevalence of
HCV, which generally is not transmitted sexually, was
lower than often found among PWID.
HIV transmission among PWID and their partners is
compounded by the sizeable proportion of HIV-positive
PWID who are not aware of their serostatus, who share
needles, and who do not use condoms [37]. Our findings
underscore the need for introducing harm reduction
programs for PWID in Mozambique, as has been done
in surrounding countries [19, 38], and especially in
Maputo where the proportion of PWID having ever re-
ceived any harm reduction or HIV prevention service
was unacceptably low, even in comparison to Nampula.
Our study has some important limitations. Although
RDS diagnostics revealed that the sample met the under-
lying assumptions needed for RDS analysis as presented
in the full survey report [21] and that recruitment equi-
librium was achieved for key variables, the Nampula/Na-
cala study site did not reach the desired sample size.
This small sample size limits the confidence around esti-
mates and reduces the ability to make significant com-
parisons between groups. There are several factors that
could have contributed to the survey not achieving sam-
ple size in Nampula, the first is that the pool to sample
from is small, estimated at 510 [21]. Secondly, police ac-
tivity around drug use was high in the area. This activity
was unrelated to the survey, but according to commu-
nity outreach workers they hampered PWID willingness
to participate. Another important limitation is that cer-
tain sub-groups of PWID were not captured; most not-
ably females who inject drugs and non-Mozambicans.
Though community outreach workers made substantial
effort to reach out to females who inject drugs in their
social networks, we had known from formative assess-
ment that fewer females than males inject drugs, and
that female injection drug users tend to be very difficult
to access. This difficulty in recruiting female inject drug
users is not unique to our study [7, 39, 40]. Our findings
are also limited by the inclusion of individuals who re-
ported lifetime, as opposed to recent, use of injection
drugs, a necessary action to overcome bottlenecks in
participant recruitment. Analysis of key variables pre-
and post- exclusion criteria change found no difference
between participant composition. HIV prevalence based
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on self-reports likely underestimate true HIV prevalence
because persons with HIV are likely reluctant to disclose
status due to stigma. The high refusal rate for hepatitis
C testing likely underestimates the true prevalence of
anti-HCV positivity in this population. Refusal for hepa-
titis C testing might be related to the lack of specific of
the point-of-care test used, or the lack of hepatitis C
treatment availability in the country. If treatment is
introduced in the future, the proportion accepting hepa-
titis C testing may change [41]. Finally, though inter-
viewers were highly trained and fluent in Portuguese
and local languages, face-to-face interviewing methods,
such as those used in this BBS, are prone to social desir-
ability bias. Despite these limitations, the results pre-
sented here provide valuable insight into HIV risk
behaviors among PWID in Mozambique that can guide
targeted harm reduction interventions and policies.
Conclusions
This was the first survey to document of the high preva-
lence of HIV, HBsAg and anti-HCV positivity among
PWID in the Mozambique. Our findings suggest imme-
diacy is needed in implementation of HIV, HBV and
HCV prevention, care and treatment services for PWID.
Additional studies may be useful to assess the feasibility
of evidence-based harm reduction interventions such as
needle and syringe exchange programs or opioid substi-
tution therapies in Mozambique.
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